What is Zacks Research's Forecast for MD Q1 Earnings?

Key Points

• Zacks Research raised its Q1 2027 EPS forecast for Pediatrix Medical Group to $0.37, up from $0.34. It projects full-year 2027 EPS of $2.10, compared with the current full-year consensus estimate of $2.15.
• Pediatrix recently reported quarterly EPS of $0.63, beating the $0.59 consensus estimate, while revenue of $487.78 million exceeded expectations and increased 4.1% year over year.
• Analyst sentiment remains cautious, with one Buy rating and six Holds, producing an overall “Hold” rating and a consensus price target of $25.00; shares recently opened at $26.22.

Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) - Equities researchers at Zacks Research raised their Q1 2027 EPS estimates for shares of Pediatrix Medical Group in a research note issued to investors on Tuesday, August 18th. Zacks Research analyst Team now forecasts that the company will earn $0.37 per share for the quarter, up from their previous forecast of $0.34. The consensus estimate for Pediatrix Medical Group's current full-year earnings is $2.15 per share. Zacks Research also issued estimates for Pediatrix Medical Group's Q3 2027 earnings at $0.57 EPS, Q4 2027 earnings at $0.63 EPS, FY2027 earnings at $2.10 EPS, Q1 2028 earnings at $0.34 EPS, Q2 2028 earnings at $0.49 EPS and FY2028 earnings at $2.04 EPS.

MD has been the subject of a number of other reports. Weiss Ratings raised shares of Pediatrix Medical Group from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, August 4th. UBS Group increased their price objective on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the company a "neutral" rating in a research report on Thursday, August 6th. Truist Financial increased their price objective on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the company a "hold" rating in a research report on Tuesday, July 14th. Mizuho set a $24.00 target price on shares of Pediatrix Medical Group in a report on Friday, May 8th. Finally, Jefferies Financial Group downgraded shares of Pediatrix Medical Group from a "buy" rating to a "hold" rating and boosted their target price for the stock from $27.00 to $28.00 in a report on Wednesday. One research analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Pediatrix Medical Group presently has an average rating of "Hold" and a consensus price target of $25.00.

Pediatrix Medical Group Stock Performance

Shares of NYSE MD opened at $26.22 on Thursday. The company has a market cap of $2.13 billion, a P/E ratio of 12.55 and a beta of 0.66. Pediatrix Medical Group has a 52-week low of $15.69 and a 52-week high of $27.94. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.32. The firm's fifty day moving average is $25.68 and its two-hundred day moving average is $22.91.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.59 by $0.04. The firm had revenue of $487.78 million for the quarter, compared to the consensus estimate of $478.49 million. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The company's revenue was up 4.1% on a year-over-year basis. During the same period last year, the firm earned $0.53 EPS.

Institutional Trading of Pediatrix Medical Group

Several institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada lifted its stake in Pediatrix Medical Group by 23.8% in the first quarter. Royal Bank of Canada now owns 22,097 shares of the company's stock worth $320,000 after acquiring an additional 4,247 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Pediatrix Medical Group by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 51,253 shares of the company's stock valued at $743,000 after purchasing an additional 2,251 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Pediatrix Medical Group by 4.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 268,506 shares of the company's stock valued at $3,891,000 after purchasing an additional 12,171 shares during the period. Cetera Investment Advisers bought a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at about $145,000. Finally, Quantbot Technologies LP bought a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at about $99,000. Institutional investors own 97.71% of the company's stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc NYSE: MD is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source